Berman Capital Advisors’s Immunic IMUX Stock Holding History

Berman Capital Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-21	Closed	-$2K	–	1499
2019 Q3	$2K	Hold	21	–	–	﹤0.01%	1192
2019 Q2	$2K	Buy	+21	New	+$2.76K	﹤0.01%	1202

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Berman Capital Advisors's IMUX Position: Q4 2019 in Review

Berman Capital Advisors sold out of Immunic (IMUX) in Q4 2019, closing a stake of 21 shares — an estimated $2K sold.

Berman Capital Advisors first reported a position in IMUX in Q2 2019 and held it in 2 quarters. The position peaked at $2K in Q3 2019. 20 funds tracked by Wall St. Rank hold IMUX as of Q4 2019.

Berman Capital Advisors reported no remaining Immunic position as of Q4 2019 after selling out during the quarter.
Berman Capital Advisors sold 21 Immunic shares in Q4 2019, an estimated $2K.
Berman Capital Advisors first reported a position in Immunic in Q2 2019 and held it in 2 quarters.
Berman Capital Advisors's Immunic position peaked at $2K in Q3 2019.
20 funds tracked by Wall St. Rank held Immunic as of Q4 2019.

Based on Berman Capital Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.